Novozymes A/S (OTCMKTS:NVZMY) Sees Large Drop in Short Interest

by · The Markets Daily

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 546 shares, a decline of 95.5% from the September 15th total of 12,081 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 47,865 shares, the short-interest ratio is currently 0.0 days.

Novozymes A/S Stock Performance

Shares of NVZMY traded up $0.97 during mid-day trading on Friday, reaching $65.26. The company had a trading volume of 24,343 shares, compared to its average volume of 24,596. The stock has a market capitalization of $27.05 billion, a P/E ratio of 41.30, a PEG ratio of 2.88 and a beta of 0.89. Novozymes A/S has a 52-week low of $49.90 and a 52-week high of $75.27. The stock has a 50 day moving average of $66.64 and a two-hundred day moving average of $62.75. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last released its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%. On average, analysts expect that Novozymes A/S will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Novozymes A/S stock. Elefante Mark B lifted its position in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors and hedge funds.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing.

Featured Stories